XNASATLN
Market cap77mUSD
Jan 06, Last price
6.55USD
1D
-5.89%
1Q
6.48%
IPO
39.75%
Name
SeqLL Inc
Chart & Performance
P/E
—
P/S
77,277.64
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-49.76%
Rev. gr., 5y
-75.52%
Revenues
1k
-97.55%
Net income
-4m
L+7.33%
CFO
0k
P
Profile
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 1 -97.55% | ||||||
Cost of revenue | 4,076 | ||||||
Unusual Expense (Income) | |||||||
NOPBT | (4,075) | ||||||
NOPBT Margin | |||||||
Operating Taxes | 98 | ||||||
Tax Rate | |||||||
NOPAT | (4,172) | ||||||
Net income | (4,193) 7.33% | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 257,973,000 | 110 | |||||
Long-term debt | 2,853,001,000 | 4,374 | |||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | 416,983,000 | (1,733) | |||||
| Cash flow | |||||||
Cash from operating activities | (3,663) | ||||||
CAPEX | (40) | ||||||
Cash from investing activities | 1,827,965,000 | 1,828 | |||||
Cash from financing activities | 1,460,399,000 | 11,995,917,000 | |||||
FCF | (1,623,704,340) | (5,567) | |||||
| Balance | |||||||
Cash | 2,693,991,000 | 6,217 | |||||
Long term investments | |||||||
Excess cash | 2,693,991,000 | 6,216 | |||||
Stockholders' equity | (24,136,271,000) | (18,486) | |||||
Invested Capital | 26,299,501,000 | 25,782 | |||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 297 | ||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (3,987) | ||||||
EV/EBITDA | |||||||
Interest | 91 | ||||||
Interest/NOPBT | |||||||